The effectiveness and safety of nanocurcumin supplementation for diabetic peripheral neuropathy in patients with type 2 diabetes: a randomized double-blind clinical trial.
Asieh Mansour, Hamid Reza Rahimi, Hadis Gerami, Atie Sadat Khorasanian, Amir Hossein Esmaeili, Atefeh Amrollahi Bioky, Mohammad Reza Mohajeri-Tehrani, Hamid Reza Fateh, Sayed Mahmoud Sajjadi-Jazi
{"title":"The effectiveness and safety of nanocurcumin supplementation for diabetic peripheral neuropathy in patients with type 2 diabetes: a randomized double-blind clinical trial.","authors":"Asieh Mansour, Hamid Reza Rahimi, Hadis Gerami, Atie Sadat Khorasanian, Amir Hossein Esmaeili, Atefeh Amrollahi Bioky, Mohammad Reza Mohajeri-Tehrani, Hamid Reza Fateh, Sayed Mahmoud Sajjadi-Jazi","doi":"10.1186/s12937-025-01184-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetic neuropathy is the most prevalent complication of diabetes mellitus, affecting up to 50% of patients with type 2 diabetes mellitus (T2DM). Among the various types of diabetic neuropathy, diabetic peripheral neuropathy (DPN) is the most common. Numerous animal studies have highlighted a strong association between the improvement of DPN and curcumin supplementation, particularly due to curcumin's anti-inflammatory and antioxidant properties. However, the effects of curcumin on DPN have been evaluated in only one randomized controlled trial. In our study, we assessed the efficacy and safety of a 16-week supplementation with nanocurcumin in T2DM patients suffering from DPN.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled trial was conducted at a diabetes clinic within the Endocrinology and Metabolism Research Center in Tehran, Iran. The study aimed to evaluate the effects of nanocurcumin (40 mg taken twice daily) compared to a placebo in patients with DPN over a 16-week period. The primary endpoint of the study was the reduction of pain severity, measured by the Numerical Rating Scale (NRS). Additionally, we assessed neuropathic outcomes by monitoring changes in the Michigan Neuropathy Screening Instrument examination (MNSIE) and the Neuropathy Disability Score (NDS). Secondary endpoints included improvements in metabolic and cardiovascular parameters from baseline to the end of the treatment.</p><p><strong>Results: </strong>Ninety-seven patients were randomized, with 41 in the nanocurcumin group and 45 in the placebo group completing the study. No significant differences were found between the groups in terms of NRS (P = 0.787), NDS (P = 0.576), or MNSIE (P = 0.405) after 16 weeks. Nanocurcumin supplementation did not alter the metabolic profile or cardiovascular parameters and was well-tolerated, without major adverse events.</p><p><strong>Conclusion: </strong>Nanocurcumin supplementation over 16 weeks did not improve pain, neuropathic outcomes, or metabolic/cardiovascular parameters in patients with T2DM suffering from DPN.</p>","PeriodicalId":19203,"journal":{"name":"Nutrition Journal","volume":"24 1","pages":"115"},"PeriodicalIF":3.8000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273300/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12937-025-01184-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Diabetic neuropathy is the most prevalent complication of diabetes mellitus, affecting up to 50% of patients with type 2 diabetes mellitus (T2DM). Among the various types of diabetic neuropathy, diabetic peripheral neuropathy (DPN) is the most common. Numerous animal studies have highlighted a strong association between the improvement of DPN and curcumin supplementation, particularly due to curcumin's anti-inflammatory and antioxidant properties. However, the effects of curcumin on DPN have been evaluated in only one randomized controlled trial. In our study, we assessed the efficacy and safety of a 16-week supplementation with nanocurcumin in T2DM patients suffering from DPN.
Methods: This randomized, double-blind, placebo-controlled trial was conducted at a diabetes clinic within the Endocrinology and Metabolism Research Center in Tehran, Iran. The study aimed to evaluate the effects of nanocurcumin (40 mg taken twice daily) compared to a placebo in patients with DPN over a 16-week period. The primary endpoint of the study was the reduction of pain severity, measured by the Numerical Rating Scale (NRS). Additionally, we assessed neuropathic outcomes by monitoring changes in the Michigan Neuropathy Screening Instrument examination (MNSIE) and the Neuropathy Disability Score (NDS). Secondary endpoints included improvements in metabolic and cardiovascular parameters from baseline to the end of the treatment.
Results: Ninety-seven patients were randomized, with 41 in the nanocurcumin group and 45 in the placebo group completing the study. No significant differences were found between the groups in terms of NRS (P = 0.787), NDS (P = 0.576), or MNSIE (P = 0.405) after 16 weeks. Nanocurcumin supplementation did not alter the metabolic profile or cardiovascular parameters and was well-tolerated, without major adverse events.
Conclusion: Nanocurcumin supplementation over 16 weeks did not improve pain, neuropathic outcomes, or metabolic/cardiovascular parameters in patients with T2DM suffering from DPN.
期刊介绍：
Nutrition Journal publishes surveillance, epidemiologic, and intervention research that sheds light on i) influences (e.g., familial, environmental) on eating patterns; ii) associations between eating patterns and health, and iii) strategies to improve eating patterns among populations. The journal also welcomes manuscripts reporting on the psychometric properties (e.g., validity, reliability) and feasibility of methods (e.g., for assessing dietary intake) for human nutrition research. In addition, study protocols for controlled trials and cohort studies, with an emphasis on methods for assessing dietary exposures and outcomes as well as intervention components, will be considered.
Manuscripts that consider eating patterns holistically, as opposed to solely reductionist approaches that focus on specific dietary components in isolation, are encouraged. Also encouraged are papers that take a holistic or systems perspective in attempting to understand possible compensatory and differential effects of nutrition interventions. The journal does not consider animal studies.
In addition to the influence of eating patterns for human health, we also invite research providing insights into the environmental sustainability of dietary practices. Again, a holistic perspective is encouraged, for example, through the consideration of how eating patterns might maximize both human and planetary health.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
